Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.50p +3.65% 71.00p 70.00p 72.00p 71.00p 69.00p 69.00p 195,438 14:47:40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.6 -8.9 -10.1 - 123

Angle Share Discussion Threads

Showing 50101 to 50124 of 50125 messages
Chat Pages: 2005  2004  2003  2002  2001  2000  1999  1998  1997  1996  1995  1994  Older
DateSubjectAuthorDiscuss
19/7/2019
15:42
Guessing - but 12m (?)new shares not showing against those with more than 3%. Wonder if they will show up soon?
semper vigilans
19/7/2019
14:07
Not sure, It's happened before but I can't buy any more than 1000 shares on line at the moment. I probably could if I phoned but they would likely be looking further down the MM's list and ask for 72p+. Chart wise It looks possible that next week may be interesting, but you never know.
jelenko
19/7/2019
13:40
Big news brewing perhaps?
spaceparallax
19/7/2019
11:14
Also interesting to note that House broker is buying at the top price.
jelenko
19/7/2019
10:49
I'm on a free Level 2 trial for a month. It has been interesting watching. Yesterday we were 2 v 1 before the tick up. After that we moved to 2 v 5. By lunch time 4 v 4. Fairly small buys were taking out the MMs. Another tick up already today. Currently 3 v 2, and in terms of volumes heavily weighted towards the MMs wanting to acquire shares. So looking strong throughout. Won't take much to push this to a 73p-70p spread today. But then why sell with the results and webcast due in just 8 trading days. No wonder the price is ticking up on the buys.
sicilian_kan
19/7/2019
10:29
Just tried a dummy buy and can't get anything from £1k upwards.
maxie23
18/7/2019
10:19
Whatever happens, we know we have the results and the analysts' meeting with live webcast on 31 July 2019. Less than two weeks now. We all know how very good Newland is at presenting. We also know how he can get a little rampy and get the market / share price excited as a result. Prospects for a rise from here in the coming days and weeks are very good.
sicilian_kan
18/7/2019
10:15
95p - 100p to test after that
fraybentos2
18/7/2019
10:11
motoring to 75p
fraybentos2
17/7/2019
17:51
htTps://ovariancancernewstoday.com/2019/07/17/blood-test-identifies-ovarian-cancer-prior-to-surgery-angle-says/
waterloo01
17/7/2019
13:15
Should get another / more holdings rns(s) this week. We've only had the US one to date and that was only half the placing. Then in two weeks we have results and the webcast that follows. So looking good on the news front.
sicilian_kan
17/7/2019
10:18
More jobs being advertised on AGL Twitter site.
semper vigilans
17/7/2019
09:19
https://www.valuewalk.com/2010/06/buffett-anounces-favorite-investors/ Full article re Greg Alexander etc.
jelenko
16/7/2019
19:45
Waterloo, Agree, it's great to see Parsortix being evaluated in clinical trials in another cancer. I'm pretty sure that this is completely independent research and that Lawson are one of Angle's customers. They are part of Western University and the Principal Investigator for the new trial is Dr Alison Allan. She seems to have been working on this project for a few years(see below). She has published several papers involving Parsortix and the preclinical research that has resulted in this trial was presented by Dr Allan at a conference in Boston back in 2017. Well worth having a look at Angle's RNS of 20th July 2017 which covers this. At the end of the RNS it states:- ' Western University is a customer of ANGLE and its research work is independent of the Company.' Also this from the RNS bodes well:- '"Of the three types of liquid biopsy technology employed in cancer management, the analysis of CTCs is the most advanced and could potentially revolutionize the treatment of cancer patients," said Dr. Allan. "The presence of CTCs can be detected early in the course of a cancer and is a fundamental prerequisite of metastasis. Their identification offers great potential not only in the diagnosis of patients but also in assessing their progression and likely outcome. When comparing the three methods used, ANGLE's Parsortix system proved to be the most advanced in its ability to harvest viable cells for downstream analysis, which is critical to research and patient care." Https://investegate.co.uk/angle-plc--agl-/rns/preclinical-study-presented-at-tumor-boston-summit/201707201300026533L/ Https://www.lawsonresearch.ca/news/identifying-spread-prostate-cancer
bermudashorts
16/7/2019
18:56
The Lawsen trial in Canada is really very interesting. One assumes Angle have had some input given it's a direct comparison between the two and builds on the work in Prostate cancer done by Barts et al. The timing could be key with headline results summer 2020. Should Parsortix be approved for use in breast cancer, if it then shows significant improvement in the quality of results in prostate cancer, as is suggested by the preamble text of the trial, then it's not impossible that it could, with minimal hurdle, be approved in prostate cancer as it shows more than equivalence to an already approved test. Add Ovarian, brain cancer et al not far behind and it's easier to see why a US fund has taken a position. "translation to the clinic." is the key phrase.
waterloo01
16/7/2019
18:20
Indeed Maxie, my thanks to SK and all who contribute. It will be interesting to see if other investors in the US, both PI and institutional follow, the lead by conifer.
auphilman
16/7/2019
18:11
Just had a chance to read the many excellent posts today. Much appreciated to all who contributed to these. At last the US have a share in Angle.
maxie23
16/7/2019
17:03
Superb posts ! Some very classy posters for a classy company! Not only punctilious literacy, but super in-depth observations. Gold standard throughout, thanks so very much.
enteleon
16/7/2019
16:21
Never seen mention of it and can't see any connection
waterloo01
16/7/2019
16:06
Any knowledgable folk know if Parsortix is involved with Glaxo/Zejula trials please? Mentioned together on Google, but I might be reading too much into it.
semper vigilans
16/7/2019
13:28
Stand corrected again. Many thanks
waterloo01
16/7/2019
13:22
SK posts crossed (again!)
bermudashorts
16/7/2019
13:22
Waterloo, Estimated completion date od 2025 is a reflection of the fact that progression free and overall survival are secondary endpoints - takes years to measure. The other endpoints have a 1 to 2 year timescale.
bermudashorts
16/7/2019
13:19
Hi waterloo01, that is a secondary outcome measure. The primary outcome measure is expected in September 20.
sicilian_kan
Chat Pages: 2005  2004  2003  2002  2001  2000  1999  1998  1997  1996  1995  1994  Older
Your Recent History
LSE
AGL
Angle
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190719 20:58:07